Thursday, October 8, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 11, 2025

Ciena (CIEN) Q4 2025 Earnings Call Transcript

View original at nasdaq.com
Ciena (CIEN) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. Date Thursday, Dec. 11, 2025 at 8:30 a.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Scale across deployments are all US-centric around the training models with hundreds of millions each in multi-year projects

    80% confidence
  • Traffic needs to leave the data center to be monetized and operationalized, and we are their strategic technology partner

    80% confidence
  • MOFN generated hundreds of millions in telco business from hyperscaler demand in FY2025

    80% confidence
  • The long-term growth guide of 8-11% is off the table as momentum continues into FY2027

    80% confidence
  • DCOM has hundreds of millions of dollars in revenue scale and is in advanced pipeline discussions with additional hyperscalers

    80% confidence
  • Ciena has the earliest view of demand due to hyperscaler relationships and is more vertically integrated than peers

    80% confidence
  • Nubis is a great cultural fit with open ecosystem CPO approach and strong customer feedback

    80% confidence
  • Third-party estimates project $7T+ capex through end of decade for all AI infrastructure

    80% confidence
  • Telco recovery with sustained mid-to-high single-digit growth expected in FY2026+ after multi-year transport underinvestment

    80% confidence
  • All new data center and AI wins are already incorporated into 2026 guidance

    80% confidence
  • In and around data center revenue will be low double-digit percentage of total revenue in FY2026 versus low single-digit in FY2025, nearly a tripling

    80% confidence
  • Coherent optics adoption has reached inflection point for use inside and around data center versus traditional long-haul/subsea

    80% confidence
  • We're essentially sold out in Q1 FY2026. If we had more supply, we'd be able to sell more

    80% confidence
  • Network is now recognized as critical bottleneck and long pole in the tent for AI operationalization

    80% confidence
  • Cloud providers have largely actually underinvested in their networks to date, particularly relative to other areas of AI infrastructure

    80% confidence
  • All three hyperscaler scale-across wins expected to generate revenue in FY2026 with major scaling in FY2027-2028

    80% confidence
  • FY2025 was a seminal year for Ciena

    80% confidence
  • Ciena gained 2 percentage points of optical market share YTD in FY2025 with further gains expected in FY2026

    80% confidence
  • Three out of the four hyperscalers have selected us for their scale across training models

    80% confidence
  • We are on a steady track of ongoing multiyear gross margin expansion

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Ciena (CIEN) Q4 2025 Earnings Call Transcript — Source | Via News | ViaNews Market